

2nd International Conference on **Epidemiology & Evolutionary Genetics**

August 18-19, 2014 DoubleTree by Hilton Beijing, China

DNA damage in lymphocytes from healthy individuals and respiratory disease patients, treated *ex vivo/in vitro* with aspirin and ibuprofen nanoparticles compared to their bulk forms

Diana Anderson¹, Mojgan Najafzadeh¹, Aftab Ali¹, Badie Jacob², Muhammad Isrib¹, Rajendran Gopalan¹ and Lijun Shang¹

¹University of Bradford, UK

²Bradford Royal Infirmary, UK

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzyme activity, a significant mechanism of action of NSAIDs. Inflammation is associated with increasing cancer incidence. Recent pre-clinical and clinical studies have shown that NSAID treatment could cause an anti-tumour effect in cancers. Such studies are lengthy and expensive. The present study, however, examined DNA damage in the Comet and micronucleus assays in peripheral blood lymphocytes of patients with respiratory diseases and healthy individuals using the nanoparticle (NP) and bulk versions of the NSAIDs, aspirin and ibuprofen. Lymphocytes are suitable surrogate cells for cancers and other disease states. DNA damage decreased in lymphocytes from healthy individuals, asthma, COPD and lung cancer patient groups after treatment with aspirin nano (ASP-N) and ibuprofen nano (IBU-N) compared to their bulk version in both assays. However, when ASP-N was compared to untreated lymphocytes in all groups in the Comet assay, DNA damage significantly decreased in all groups, except the asthma group. When IBU-N was compared to untreated lymphocytes, in healthy individuals and the lung cancer group, DNA damage decreased, but increased in asthma and COPD groups. Similarly, micronuclei (MNi) increased after ASP-N and IBU-N in the healthy individual and lung cancer groups, and decreased in asthma and COPD groups. Furthermore, lymphocytes responses after IBU-N and ibuprofen bulk were investigated by the physiological patch-clamp technique. Patch-clamp recordings demonstrated that IBU-N inhibited ion channel activity by 20%. This molecular epidemiology approach mirrors pre-clinical and clinical findings, and provides further information using nanoparticles.

Biography

Diana Anderson currently holds the Established Chair of the Division of Biomedical Sciences at the University of Bradford, UK. She obtained her first degree in the University of Wales and second degree in the Faculty of Medicine, University of Manchester. After tutoring at the University of Sydney, Australia, she became a research worker in the Department of Cancer Studies at the University of Leeds and at the Paterson Laboratories, Christie Hospital, Manchester. She has organized both National and International meetings and was/is a member of various national (e.g. MRC Advisory Board, Veterinary Products Committee) and was of International committees, including the European Union Scientific Committee for Animal Nutrition (SCAN). She recently won a prize as an Enterprise Fellow. She has hosted and participated in 56 meetings for WHO/IPCS. She is a consultant for many international organizations, such as the WHO, NATO, TWAS, UNIDO and the OECD.

D.Anderson1@bradford.ac.uk